IsoPlexis has been granted a patent for a polymerase enzyme derived from 9° N, featuring mutations in the motif A region for improved nucleotide incorporation. The enzyme, with specific mutations, offers enhanced functionality and minimal 3′-5′ exonuclease activity. GlobalData’s report on IsoPlexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights IsoPlexis Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on IsoPlexis, was a key innovation area identified from patents.

Polymerase enzyme with improved nucleotide incorporation and no exonuclease activity

Source: United States Patent and Trademark Office (USPTO). Credit: IsoPlexis Corp

A recently granted patent (Publication Number: US11866741B2) discloses a novel polymerase enzyme with specific mutations that result in little to no 3'-5' exonuclease activity. The enzyme, sharing a high amino acid sequence identity with a specified sequence, is particularly useful for incorporating modified nucleotides with larger substituents into DNA. The polymerase, derived from organisms belonging to the genera of Pyrococcus, can also contain additional mutations to enhance its functionality, as outlined in the claims.

Furthermore, the patent covers the nucleic acid molecule encoding the unique polymerase, an expression vector containing this nucleic acid molecule, and methods for incorporating modified nucleotides into DNA using the polymerase. The patent also highlights the diverse applications of this polymerase, including DNA sequencing, labeling, primer extension, and nucleic acid amplification. Additionally, a kit comprising the polymerase is provided for convenient use in various molecular biology applications. Overall, the patented polymerase enzyme offers a promising tool for researchers and professionals in the field, enabling the efficient incorporation of modified nucleotides into DNA for a wide range of applications.

To know more about GlobalData’s detailed insights on IsoPlexis, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies